cd38 chimeric antigen receptor t cells + cs1 chimeric antigen receptor t cells

cd38 chimeric antigen receptor t cells + cs1 chimeric antigen receptor t cells refers to a dual-targeted cellular immunotherapy approach designed for the treatment of relapsed or refractory multiple myeloma. This therapy involves autologous T cells that are genetically engineered to express chimeric antigen receptors (CARs) specific for two distinct antigens highly expressed on malignant plasma cells: CD38 and CS1 (also known as SLAMF7 or CD319). CD38 is a transmembrane glycoprotein with ectoenzymatic activity, while CS1 is a member of the Signaling Lymphocyte Activation Molecule (SLAM) family. By targeting both antigens simultaneously—either through the use of a single T cell expressing both receptors (dual/bispecific CAR) or a cocktail of separate CAR-T products—the therapy aims to enhance tumor recognition and prevent immune escape, which frequently occurs through the downregulation of a single target antigen. Clinical development is primarily centered in academic institutions and specialized biotech firms in China, demonstrating promising results in achieving deep clinical responses in patients with advanced plasma cell malignancies.

Other names

CD38 and CS1 dual-targeted CAR-T cellsCD-38 and CS1 dual-targeted CAR-T cellsCD 38 and CS1 dual-targeted CAR-T cellsCD38-CS1 bispecific CAR-T cellsCD-38-CS1 bispecific CAR-T cellsCD 38-CS1 bispecific CAR-T cellsCD38-CS1-targeted CAR-T cellsCD-38-CS1-targeted CAR-T cellsCD 38-CS1-targeted CAR-T cellsAnti-CD38 and anti-CS1 CAR-T cell therapyAnti-CD-38 and anti-CS1 CAR-T cell therapyAnti-CD 38 and anti-CS1 CAR-T cell therapy